SLAMF7 is an immune receptor with broad functions in adaptive and innate immunity. As a signaling lymphocytic activation molecule family member, SLAMF7 regulates natural killer cell activation and macrophage function 1. Mechanistically, SLAMF7 engagement drives inflammatory cytokine expression, particularly TNF-α, through autocrine amplification loops 1. In hepatocellular carcinoma, SLAMF7 suppresses CCL2 expression via SHB-mediated SHIP1 recruitment and TRAF6 deubiquitination, limiting immunosuppressive macrophage infiltration 2. SLAMF7 and SLAMF8 cooperatively regulate plasmacytoid dendritic cell responses to intracellular bacteria through NF-κB, IRF7, and STAT-1 signaling, controlling mitochondrial ROS levels 3. Clinically, SLAMF7 represents a validated therapeutic target in multiple myeloma; elotuzumab targeting SLAMF7 gained FDA approval in 2015 4. Genetic studies implicate SLAMF7 in multiple sclerosis pathogenesis—elevated cerebrospinal fluid SLAMF7 levels reduce MS risk (OR, 0.42), suggesting it as a promising drug target 5. SLAMF7 expression correlates with immunotherapy responsiveness in hepatocellular carcinoma, serving as a potential predictive biomarker 2. Additionally, SLAMF7+ cytotoxic T cells participate in IgG4-related disease pathogenesis 6. These findings establish SLAMF7 as a multifunctional immune regulator with significant disease relevance across hematologic malignancies, autoimmune conditions, and infection.